← All companies

XERS

Xeris Biopharma Holdings, Inc.

XERS Nasdaq Pharmaceutical Preparations EDGAR ↗

$8.13

+0.05 +0.62%

Key statistics

from XBRL data in SEC filings

Market cap

$1.40B

Revenue (TTM)

$315M

Net income (TTM)

$12.0M

EPS (TTM)

$0.07

P/E ratio

116.1

Dividend yield

—

Free cash flow

$27.5M

Cash

$112M

Total assets

$392M

Gross margin

—

52-week range

$5.25 – $10.08

Recent SEC filings

40 most recent

Annual, quarterly & current reports

8-K Unregistered sale of equity; Other events Jul 17, 2026 8-K Director or officer change; Regulation FD disclosure Jun 30, 2026 8-K Unregistered sale of equity; Other events Jun 11, 2026 8-K Shareholder vote results Jun 5, 2026 10-Q Quarter ended 2026-03-31 May 7, 2026 8-K Results of operations (earnings release) May 7, 2026 8-K Director or officer change Apr 21, 2026 10-K Fiscal year ended 2025-12-31 Mar 2, 2026 8-K Results of operations (earnings release) Mar 2, 2026 8-K Regulation FD disclosure Feb 27, 2026 8-K Results of operations (earnings release) Jan 8, 2026 8-K Regulation FD disclosure Dec 1, 2025 10-Q Quarter ended 2025-09-30 Nov 6, 2025 8-K Results of operations (earnings release) Nov 6, 2025 10-Q Quarter ended 2025-06-30 Aug 7, 2025 8-K Results of operations (earnings release) Aug 7, 2025 8-K Shareholder vote results Jun 4, 2025 8-K Regulation FD disclosure Jun 3, 2025 10-Q Quarter ended 2025-03-31 May 8, 2025 8-K Results of operations (earnings release) May 8, 2025 8-K Director or officer change; Regulation FD disclosure Mar 28, 2025 10-K Fiscal year ended 2024-12-31 Mar 6, 2025 8-K Results of operations (earnings release) Mar 6, 2025 8-K Director or officer change; Regulation FD disclosure Feb 24, 2025 8-K Results of operations (earnings release) Jan 10, 2025 10-Q Quarter ended 2024-09-30 Nov 8, 2024 8-K Results of operations (earnings release) Nov 8, 2024 10-Q Quarter ended 2024-06-30 Aug 8, 2024 8-K Results of operations (earnings release) Aug 8, 2024 8-K Director or officer change Aug 2, 2024 8-K Results of operations (earnings release); Director or officer change; Regulation FD disclosure Jul 8, 2024 8-K Director or officer change; Shareholder vote results Jun 5, 2024 10-Q Quarter ended 2024-03-31 May 9, 2024 8-K Results of operations (earnings release) May 9, 2024 10-K Fiscal year ended 2023-12-31 Mar 6, 2024 8-K Entered a material agreement; Results of operations (earnings release); Took on a direct financial obligation; Other events Mar 6, 2024 8-K Results of operations (earnings release) Jan 4, 2024 10-Q Quarter ended 2023-09-30 Nov 9, 2023 8-K Results of operations (earnings release) Nov 9, 2023 8-K Regulation FD disclosure Oct 16, 2023